Post-authorization, Observational Study to Evaluate the Effectiveness of Adalimumab (HUMIRA) on Moderate-severe Psoriasis Under Conditions of Routine Clinical Practice in Spain.
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PROMISE
- Sponsors AbbVie
- 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jan 2013 Planned end date changed from 1 Aug 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 01 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.